aPALACE 1-3 pooled analysis. Data as observed; includes all patients who received OTEZLA 30 mg BID, regardless of whether they were initially randomized to OTEZLA 30 mg BID or placebo patients who were re-randomized to OTEZLA at week 16 or week 24.
Patients treated with OTEZLA 30 mg BID achieved significantly greater improvement vs placebo in dactylitis count (mean change of -1.8 vs -1.3, P<0.01) at week 242†
*Pooled patient data from PALACE 1-3; includes all randomized patients with dactylitis (baseline dactylitis count >0; n = 633). Resolution was defined as a dactylitis count of 0.
†LOCF; for patients who qualified for early escape at week 16, the week 16 value was carried forward.
BID, twice daily; LOCF, last observation carried forward; PALACE, Psoriatic Arthritis Long-Term Assessment of Clinical Efficacy.
aLAPIS-PsA study, interim analysis at 4 months. Data as observed among patients with value available at specified time point.
In a real-world clinical setting, OTEZLA led to complete resolution of dactylitis2†
*Among patients with dactylitis count >0 at baseline (n = 32/110, 29.9%).
†Defined as dactylitis count = 0.
LAPIS-PsA, Study of Apremilast Use in Patients with Psoriatic Arthritic in Practice Conditions.
On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).